Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 6/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.43 |
| ▸ | CDK2 | P24941 | 5/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 5/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | IKBKB | O14920 | 4/20 | 0.39 |
| ▸ | CHUK | O15111 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22005019 | 0.81 | CHEK1 (0.42) | CHEK1CCNA2CDK2CCNA1HTR2A | |
| SCHEMBL22005415 | 0.77 | DDB1 (0.48) | CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL22004876 | 0.74 | HTR2A (0.43) | CHEK1CCNA2CDK2CCNA1HTR2A | |
| SCHEMBL22005063 | 0.73 | HTR2A (0.40) | CHEK1CCNA2CDK2CCNA1HTR2A | |
| SCHEMBL22005425 | 0.72 | RPLP1 (0.38) | CHEK1CCNA2CDK2CCNA1HTR2A | |
| SCHEMBL22005006 | 0.68 | RPLP1 (0.39) | HTR2A | |
| SCHEMBL29777384 | 0.68 | CHEK1 (0.46) | CHEK1CCNA2CDK2CCNA1HTR2A | |
| SCHEMBL11223267 | 0.67 | HTR6 (0.47) | HTR2A | |
| SCHEMBL24711141 | 0.66 | DDB1 (0.48) | HTR2A | |
| Hydrochloric Acid SCHEMBL11228096 | 0.66 | HTR6 (0.46) | HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200157092-A1 | [1,2,4]-TRIAZOLO [1,5-A]-PYRIMIDINYL DERIVATIVES SUBSTITUTED WITH PIPERIDINE, MORPHOLINE OR PIPERAZINE AS OGA INHIBITORS | Janssen Pharmaceutlca NV (BE) | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157092-A1 | [1,2,4]-TRIAZOLO [1,5-A]-PYRIMIDINYL DERIVATIVES SUBSTITUTED WITH PIPERIDINE, MORPHOLINE OR PIPERAZINE AS OGA INHIBITORS | OGA, PSEN1, PSEN2 | CHEK1 358/4885CCNA2 965/4885CDK2 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.